The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting progress within the regenerative medicine sector, Organogenesis announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for ReNu. This product is designed for the treatment of symptomatic knee osteoarthritis, and the application has been accepted for formal review following the completion of the filing determination. According to reports, this acceptance marks a significant regulatory milestone, clearing the way for a substantive review by health authorities.
This development comes as the biotech sector sees intensifying competition to develop non-surgical treatments for osteoarthritis, a market valued at billions of dollars globally. Compared to peers, Organogenesis aims to strengthen its position with ReNu, an amniotic suspension allograft. Per market data, ORGO stock closed at $2.36 (close July 2, 2026), with the share price fluctuating between a day low of $2.34 and a day high of $2.48 during that session.
Investors should monitor the FDA's review timeline, as any updates regarding the final decision date will be a primary catalyst for the stock. Based on available data, ORGO shares stood at $2.36 as of the close on July 2, 2026. In the absence of direct macroeconomic catalysts in the upcoming calendar specifically targeting the biotech sector, focus remains on the company's specific regulatory progress.